Trial · NCT00620945
Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass
NCT00620945, Not applicable, Terminated, The Cleveland Clinic; results first posted 2017-11-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass. Trials, record NCT00620945. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00620945
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass
- NCT number
- NCT00620945
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 87 participants, actual
- Lead sponsor
- The Cleveland Clinic
- Conditions
- Congenital Heart Surgery, Cardiopulmonary Bypass
- Interventions
- Phenoxybenzamine
- First posted
- 2008-02-22
- Last updated
- 2017-12-19
- Results first posted
- 2017-11-20
- Limitations and caveats
Due to a change in leadership the protocol of cardiopulmonary bypass was changed on 9/22/2008. The high flow low pressure perfusion is no longer used. As a result phenoxybenzamine was no longer able to be studied and the study was closed early.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Achieving High Flow Low Pressure on Cardiopulmonary Bypass | From time of cardiopulmonary bypass initiation until the time that high flow, low pressure on cardiopulmonary bypass was achieved, assessed up to 1 hour | Percentage of patients who achieved high flow, low pressure on cardiopulmonary bypass |
| Secondary | Mortality | 30 days | Percentage of patients who died within 30 days of the procedure |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Achieving High Flow Low Pressure on Cardiopulmonary Bypass | From time of cardiopulmonary bypass initiation until the time that high flow, low pressure on cardiopulmonary bypass was achieved, assessed up to 1 hour | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Mortality | 30 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Achieving High Flow Low Pressure on Cardiopulmonary Bypass | Phenoxybenzamine Treatment | 87 | Participants | ||
| Mortality | Phenoxybenzamine Treatment | 5 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phenoxybenzamine Treatment | 87 | |
| Overall Study | COMPLETED | Phenoxybenzamine Treatment | 87 | |
| Overall Study | NOT COMPLETED | Phenoxybenzamine Treatment | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Myocardial dysfunction | Cardiac disorders | Phenoxybenzamine | 3 | 87 | 3 |
| serious | Pulmonary hypertension | Vascular disorders | Phenoxybenzamine | 2 | 87 | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Phenoxybenzamine | 5 | 87 |
| Total, other adverse events | Phenoxybenzamine | 0 | 87 |
| Total, serious adverse events | Phenoxybenzamine | 5 | 87 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00620945
GET https://conductscience.org/api/trials/v1/NCT00620945/registered